Vistagen appoints elissa cote as chief corporate development officer

South san francisco, calif.--(business wire)--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of elissa cote as chief corporate development officer. in this role, ms. cote will lead the evaluation of strategic opportunities to advance vistagen's pherine platform toward potential commercial la.
VTGN Ratings Summary
VTGN Quant Ranking